Home/ Stocks/ OGEN

Oragenics Inc.

OGEN XASE

$0.55 +0.01 (+1.17%) ▲ 15-min delayed

Open

$0.55

High

$0.55

Low

$0.54

Volume

13.9K

Market Cap

$2.45M

About Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 3 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-2,201,243	$-0.51
FY 2025	$0	$-9,842,487	$-4.56
Q3 2025	$0	$-3,066,589	$-1.96
Q2 2025	$0	$-2,272,035	$-3.10

Earnings & Analyst Ratings

Next Earnings: Thu, Nov 5, 2026

Calendar →

Related Market News

No specific coverage for OGEN yet. Check out our latest market news or earnings calendar.

Get OGEN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Oragenics Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.